1173 related articles for article (PubMed ID: 23475261)
21. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.
Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L
Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic intraepithelial neoplasia in patients with intraductal papillary mucinous neoplasms: the interest of endoscopic ultrasonography.
Maire F; Couvelard A; Palazzo L; Aubert A; Vullierme MP; Rebours V; Hammel P; Sauvanet A; Levy P; Ruszniewski P
Pancreas; 2013 Nov; 42(8):1262-6. PubMed ID: 24152960
[TBL] [Abstract][Full Text] [Related]
23. Intraductal papillary mucinous neoplasm.
Shi C; Hruban RH
Hum Pathol; 2012 Jan; 43(1):1-16. PubMed ID: 21777948
[TBL] [Abstract][Full Text] [Related]
24. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.
Klöppel G; Lüttges J
Curr Gastroenterol Rep; 2004 Apr; 6(2):111-8. PubMed ID: 15191688
[TBL] [Abstract][Full Text] [Related]
25. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
[TBL] [Abstract][Full Text] [Related]
26. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm.
Sanada Y; Hirose Y; Osada S; Tanaka Y; Takahashi T; Yamaguchi K; Yoshida K
Anticancer Res; 2010 Jul; 30(7):2995-3003. PubMed ID: 20683045
[TBL] [Abstract][Full Text] [Related]
28. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms.
Moriya T; Kimura W; Semba S; Sakurai F; Hirai I; Ma J; Fuse A; Maeda K; Yamakawa M
Int J Gastrointest Cancer; 2005; 35(2):111-9. PubMed ID: 15879625
[TBL] [Abstract][Full Text] [Related]
29. Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions.
Recavarren C; Labow DM; Liang J; Zhang L; Wong M; Zhu H; Wang J; Francis F; Xu R
Hum Pathol; 2011 Jan; 42(1):18-24. PubMed ID: 21056895
[TBL] [Abstract][Full Text] [Related]
30. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions.
Räty S; Sand J; Laukkarinen J; Vasama K; Bassi C; Salvia R; Nordback I
Pancreatology; 2013; 13(5):530-3. PubMed ID: 24075519
[TBL] [Abstract][Full Text] [Related]
31. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
32. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities.
Lüttges J; Klöppel G
Dig Dis; 2001; 19(1):15-23. PubMed ID: 11385247
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
[TBL] [Abstract][Full Text] [Related]
34. Dermokine expression in intraductal papillary-mucinous neoplasm and invasive pancreatic carcinoma.
Watanabe K; Oochiai T; Kikuchi S; Kumano T; Matsui T; Morimoto K; Yasukawa S; Nakamori S; Sasako M; Yanagisawa A; Otsuji E
Anticancer Res; 2012 Oct; 32(10):4405-12. PubMed ID: 23060565
[TBL] [Abstract][Full Text] [Related]
35. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
36. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
Körner M; Hayes GM; Rehmann R; Zimmermann A; Friess H; Miller LJ; Reubi JC
Am J Pathol; 2005 Oct; 167(4):959-68. PubMed ID: 16192632
[TBL] [Abstract][Full Text] [Related]
37. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M
Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622
[TBL] [Abstract][Full Text] [Related]
38. [Neoplastic intraepithelial lesions of pancreatic ducts: new entities].
Bedossa P
Ann Pathol; 2002 Oct; 22(5):357-66. PubMed ID: 12483153
[TBL] [Abstract][Full Text] [Related]
39. EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.
Kuroki H; Hayashi H; Okabe H; Hashimoto D; Takamori H; Nakahara O; Nakagawa S; Fukushima Y; Chikamoto A; Beppu T; Hirota M; Iyama K; Baba H
PLoS One; 2014; 9(8):e100904. PubMed ID: 25084021
[TBL] [Abstract][Full Text] [Related]
40. Gli2 protein expression level is a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms.
Sugiyama Y; Sasajima J; Mizukami Y; Koizumi K; Kawamoto T; Ono Y; Karasaki H; Tanabe H; Fujiya M; Kohgo Y
Pol J Pathol; 2016 Jun; 67(2):136-44. PubMed ID: 27543868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
